Corona vaccine expected by November, Patna AIIMS hopes to test

This is promising news for the world struggling with Coronavirus infection. If all goes well, the production of Corona's Vaccine will start in India by the end of November. Such expectation has been expressed by Dr. CM Singh, Superintendent of All India Institute of Medical Sciences (AIIMS), Patna. Actually, the first phase of human trials on 40 volunteers in the institute has yielded positive results. For those who have been given the first dose, the process of giving the second dose will be started from July 29. The side effects of the vaccine on the human body are zero.

Corona vaccine expected by November, Patna AIIMS hopes to test

In Patna AIIMS, 40 people did not get any side effects of the first dose of antigen. Three people had injection pain. If all goes well, the production of indigenous vaccine will start in November this year.

The last dose will be given in October

The person who was given the first dose of corona's vaccine 5 mg on 15 July in Patna AIIMS will be given the second dose on 29 July and the third dose on 12 August. The fourth dose will be given on 26 August and the fifth on 24 October. Antibodies are tested before all doses.

Antibody test every 14 days

Vaccine testing on 40 people in the country has been possible only in Bihar. Antibodies will be tested every 14 days in the body of healthy people who have been given vaccine doses. An antibody test will take place 52 days after the fourth dose. The final investigation will be done after 194 days.

According to AIIMS management, 70 people have been tested for human trial so far, with 17 being disqualified for being corona positive. Patna AIIMS stands first and PGI Rohtak in second place in the first phase trial.

First and second phase

The first phase of the corona's vaccine trial is to be conducted on 375 people across the country. In the second phase, this test is to be done on 750 people. In the first phase, there will be people in the age group of 18 to 55 while in the second phase, people between 12 and 65 years will be tested.

Corona vaccine expected by November, Patna AIIMS hopes to test

Two big news on homegrown vaccine, BCG vaccine with Covaxin is also expected

Amid growing infection of the coronavirus, good news is coming from many countries around the world about the vaccine. Seven companies in India are also involved in preparing the corona's vaccine. Human trials of vaccine Covaxin prepared by ICMR and Bharat Biotech have started in other institutes including Delhi AIIMS, Patna AIIMS, Rohtak PGI, on the other hand, Zydus Cadila also got the human trial process after getting approval from the Controller General of India (DGCI). Has started At the same time, another vaccine already available seems to be raising hopes against the coronavirus.

Coronavirus vaccine work is going on fast in the country. Trial of ICMR-Bharat Biotech's Covaxin has also started in Bhubaneswar, Odisha after Delhi AIIMS, Patna AIIMS, Rohtak PGI. This vaccine has been applied to a select few who volunteered to be part of this trial. Volunteers who have been vaccinated were kept under observation and, according to experts, had no side effects or side effects.

The trial of Covaxin has started at the Institute of Medical Sciences and SUM Hospital, one of the 12 institutes selected by the ICMR, the Indian Council of Medical Research for vaccine trials. Dr. E. Venkata Rao, the principal researcher of the Human Trial, said that the volunteers who had come forward for the vaccine trial had to undergo the necessary screening process and were then given a dose of the vaccine under the protocol set by DCGI.

Dr. E. Venkata Rao said that the volunteers taking the vaccine dose would be given two doses in a span of 14 days. Professor in the Department of Community Medicine in the hospital According to Rao, there was a lot of enthusiasm among the people who came forward for the human trial. He said that the response from the people is very encouraging. A large number of people are coming forward to be part of the trial.

Corona vaccine expected by November, Patna AIIMS hopes to test

Covaxin is developed by the India Biotech company with the help of ICMR's Pune based National Institute of Virology (NIV, Pune). The scientific name for this vaccine is BBV152, while it is commonly named Covaxin. 12 institutes in the country have been selected for the trial of this vaccine. Trial has started in many places, while the process is going on in the remaining places.

A research study against coronavirus recently revealed that the risk of corona is less in countries where BCG vaccination is more. This vaccine is given to protect against TB, also known as tuberculosis, tuberculosis or tuberculosis. The study was conducted by the New York Institute of Technology's Department of Biomedical Sciences, which was also objected to. However, the Indian company Serum India started a trial against Corona to know its effect, which is getting good results.

The Serum Institute of India (SII) is conducting a clinical trial of Phase III of the BCG vaccine. According to the Biotechnology Department (DBT), about six thousand people have registered for this trial. These six thousand people include health workers as well as those who are facing greater risk of corona virus infection.

BCG produces immunity against TB

To protect against TB, newborns are given BCG vaccine. The National Child Immunization Program is run in Bharam. Tuberculosis is actually caused by bacteria, in which the lungs are greatly affected. According to Renu Swaroop, Secretary, Department of Biotechnology (DBT), BCG is a certified vaccine and its evaluation is a behavioral approach in treating diseases other than TB.

Will RBCG increase immunity against Corona?

In the trial of the Serum Institute, scientists will now try to find out how effective BCG Vaccine VPM1002 is in reducing the effects of infection in those facing the greatest risk of corona, the elderly, patients with complex diseases. This is a third phase trial and it will be explored whether RBCG is effective in strengthening immunity against coronavirus.

Corona vaccine expected by November, Patna AIIMS hopes to test

World's largest trial started on Corona's vaccine

The world's largest trial began on Monday in order to make the coronavirus vaccine. 30 thousand people have participated in this trial. Among the efforts that are being made to search for the corona's vaccine around the world, the vaccine which is in the last phase includes America. However, as of now there is no guarantee that this vaccine, created through the National Institute of Health and Moderna Inc., will truly protect the corona. Volunteers will also not be told whether they have been given the original vaccine or tested with a fake vaccine.

After two doses, scientists will study very closely that which group is more infected during their daily work, especially in areas where the virus has not been controlled yet and they are rapidly is spreading.

In the US, Corona specialist Doctor Anthony Fauchi recently said, "Unfortunately there are too many infected people in America to know the answer." Moderna says the vaccine was tested in Savannah, Georgia, one of more than seven dozen trial centers spread across the US.

Melissa Harting, a nurse working in Binghamton, New York, is also one of 30,000 volunteers. He said that he considered it his duty to help in this work. Harting said, 'I'm very curious. It is very important for me to eliminate this virus, along with those who are at the forefront of the battle of Corona, who are at risk of virus infection. '

The final-stage test of the vaccine, created through Oxford University in China and Britain, began earlier this month in Brazil and other more affected countries, but it is necessary for any vaccine to be used in the US to be tested in the US itself Hua Ho and the trial scale in the US is also high.

Every month a new research will be made public about the candidate going forward in search of the covid-19 Prevention Network Vaccine running from government funds. The purpose of the research that is being done on such a large scale is not just to know whether the vaccine is working or not, but every possible vaccine is safe or not and it also needs to be tested and from the same scale of research, scientists should Comparing the vaccine will help.

Corona vaccine expected by November, Patna AIIMS hopes to test

Final test of Oxford vaccine, preparations to test BCG vaccine as well

Five locations in the country have been confirmed for the third and final human trial of the AstraZeneca vaccine developed by Oxford for the diagnosis of corona. Complete preparation for the test has been done. In this phase, the vaccine will be tested on thousands of people. The Serum Institute of India is conducting a clinical trial of Phase III of the BCG vaccine. In this, it will be tested whether the BCG vaccine is effective in strengthening the resistance.

AstraZeneca will produce

This is a necessary step as data from within the country is required to be available before the vaccine is given to Indians. Oxford has selected the world's largest vaccine manufacturer, The Serum Institute of India (SII), and its partner AstraZeneca for its production following the vaccine's success. The first two-stage test results were published earlier this month.

This test is considered very important

The Department of Biotechnology (DBT) is part of the efforts of any Corona's vaccine in India. DBT is establishing a clinical site for the third phase of the Oxford vaccine. We have selected five locations for Phase III testing. The DBT Secretary said that this third test of serum is important. Earlier, on 20 July, scientists announced that the vaccine developed by Oxford University to treat coronavirus appears to be safe.

Preparation of the third stage trial of BCG vaccine

Serum Institute of India Phase III to test the effect of BCG vaccine VPM-1002 in reducing infection and its side effects in older people, patients suffering from complex diseases and medical personnel facing the highest risk of corona Performing clinical trials. According to a statement by the Department of Biotechnology (DBT), about six thousand health workers and those facing more danger have registered themselves for clinical trials. This test will explore whether the BCG vaccine is effective in strengthening immunity against the coronavirus.